Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Phase 2 Completed
78 enrolled
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 2 Completed
42 enrolled
V-CHANCE
Phase 2 Unknown
39 enrolled
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
Phase 2 Recruiting
48 enrolled
ELANFIT
Phase 2 Completed
85 enrolled
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Phase 2 Terminated
23 enrolled 8 charts
Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab
Phase 2 Completed
133 enrolled
EXTAX
Phase 2 Terminated
17 enrolled 8 charts
Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
Phase 2 Completed
14 enrolled 17 charts
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
Phase 2 Completed
36 enrolled 11 charts
MetAction
Phase 2 Completed
50 enrolled
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
Phase 2 Terminated
21 enrolled 8 charts
REGAIN
Phase 2 Terminated
2 enrolled
Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer
Phase 2 Completed
41 enrolled 11 charts
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
Phase 2 Completed
73 enrolled
Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement
Phase 2 Terminated
9 enrolled 12 charts
Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
Phase 2 Completed
43 enrolled 6 charts
OPUS
Phase 2 Completed
344 enrolled 21 charts
FUTURE
Phase 2 Completed
302 enrolled 18 charts
BALI-1
Phase 2 Completed
181 enrolled 15 charts
Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2 Withdrawn
ERBIFORT
Phase 2 Completed
24 enrolled
Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer
Phase 2 Unknown
100 enrolled
Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy
Phase 2 Completed
87 enrolled 14 charts
Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery
Phase 2 Completed
45 enrolled
Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma
Phase 2 Completed
250 enrolled
Dux
Phase 2 Unknown
50 enrolled
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
Phase 2 Unknown
35 enrolled
SPaCe-01
Phase 2 Completed
86 enrolled